Wigginton

Bright Peak Therapeutics Presents New Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Tuesday, April 9, 2024
TME, Development, Biotechnology, Cell, Teff, SAN, Tumor microenvironment, Cancer, AACR, Neoplasm, Wigginton, Huangshan, Autoimmune disease, PD-1, Vaccine

Bright Peak has leveraged its world-class protein engineering capabilities to functionally optimize the master cytokine IL-18, by creating an IL-18 binding protein-resistant molecule and integrating it with PD-1 checkpoint blockade to create BPT567, a first-in-class PD1-IL18 immunoconjugate.

Key Points: 
  • Bright Peak has leveraged its world-class protein engineering capabilities to functionally optimize the master cytokine IL-18, by creating an IL-18 binding protein-resistant molecule and integrating it with PD-1 checkpoint blockade to create BPT567, a first-in-class PD1-IL18 immunoconjugate.
  • Antibody-cytokine conjugates leverage orthogonal mechanisms of action (MoA) in one molecule to induce potent antitumor immune responses.
  • “BPT567 is designed to coordinately engage antigen-experienced Teff cells that are known to co-express both PD-1 and the IL-18 receptor.
  • It is anticipated that this profile could ultimately contribute to an improved risk-benefit profile for BPT567 in the clinical setting”.

Viewpoint Collaborates with Mama Justice to Spotlight Innovation and Client Well-being in the Personal Injury Law Sector

Retrieved on: 
Wednesday, December 6, 2023
Mama, Empowerment, Heart, Inspirational Journey, Wigginton, Private law, Partnership, Tourism, Marketing, Inclusive, Melissa

MIAMI, Dec. 6, 2023 /PRNewswire-PRWeb/ -- Viewpoint, the renowned educational program hosted by actor Dennis Quaid, is pleased to announce an exciting collaboration with Mama Justice, a forward-thinking law firm dedicated to empowering clients and championing inclusivity within the personal injury law sector. This partnership will result in a captivating new segment that will delve into the innovative approaches taken by Mama Justice, emphasizing the well-being of their clients.

Key Points: 
  • Scheduled for filming on December 8th, 2023, this insightful segment will provide a unique glimpse into the personal injury law sector's transformation through the eyes of Melissa "Missy" Wigginton, founder and visionary behind Mama Justice.
  • At the heart of this collaboration is the shared commitment to innovation and the well-being of clients within the personal injury law sector.
  • Missy Wigginton's Inspirational Journey: Missy Wigginton's personal story of loss, healing, and the creation of Mama Justice will serve as a powerful testament to the transformative potential within the personal injury law sector.
  • We are thrilled to bring their innovative approach to our viewers and share the remarkable impact they are making in the personal injury law sector."

Gifted Healthcare Announces Tech Leader Craig Wigginton as New CIO

Retrieved on: 
Thursday, May 4, 2023
AT, Health, Telecommunications, Health care, Wigginton, CIO, AI, Automation, Management, Nursing, Northeastern University

NEW ORLEANS, May 4, 2023 /PRNewswire/ -- Gifted Healthcare, a leading healthcare staffing agency, announced that Craig Wigginton has been named Chief Information Officer (CIO).

Key Points: 
  • NEW ORLEANS, May 4, 2023 /PRNewswire/ -- Gifted Healthcare, a leading healthcare staffing agency, announced that Craig Wigginton has been named Chief Information Officer (CIO).
  • "Our team continues to invest in automation and AI technology to enhance the experience of our clients and clinicians," said Dennis Ducham, CEO of Gifted Healthcare.
  • "Craig Wigginton is a highly experienced and accomplished leader in the healthcare technology space, and he will provide essential insight and lead our teams as we continue to develop these initiatives."
  • Craig Wigginton brings to Gifted more than two decades of experience in technology leadership roles, including cloud software, customer experience, and technology operations.

Icario Names Marc Willard Chief Executive Officer

Retrieved on: 
Monday, January 9, 2023
CVC, Education, Medicaid, Data, Pressure, PHE, Public health emergency (United States), Health, Interagency Coordinating Committee on the Validation of Alternative Methods, Medicare, Public health emergency, Growth, HRA, Certify Data Systems, Investment, Wigginton, Management, Risk management, Health insurance, Humana

MINNEAPOLIS, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Icario , the healthcare industry’s largest health action company, today announced the appointment of Marc Willard as CEO.

Key Points: 
  • MINNEAPOLIS, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Icario , the healthcare industry’s largest health action company, today announced the appointment of Marc Willard as CEO.
  • Having spent the last three decades leading and building healthcare technology businesses, Willard brings highly relevant experiences and industry relationships to his new role as Icario’s CEO.
  • After successfully scaling Transcend Insights, Willard later joined Humana’s leadership team as senior vice president, leading all digital patient, member and provider experiences.
  • “I am excited to join Icario at a time when healthcare payers and providers face increasing pressure to connect with their members to drive quality and outcomes,” said Willard.

Bright Peak Therapeutics Announces the Appointment of Cancer Immunotherapy Leader Jon Wigginton, M.D., as President of Research and Development

Retrieved on: 
Monday, August 22, 2022
B.S, CA, Patient, Macrogen, University, National Cancer Institute, BMS, Cancer, Immunotherapy, Bristol Myers Squibb, Autoimmune disease, Degenerative disease, IND, Group medical practice in the United States, SAN, Nivolumab, Board, Head, Â, Science, Cytokine, Huangshan, Wigginton, Peak, GLOBE, Coronavirus Scientific Advisory Board (Turkey), Leadership, Biology, Center, Board of directors, Biotechnology, IL-27, NCI, Senior advisor, Director, Society for Immunotherapy of Cancer, National, Drug development, Discovery, Society, Research and development, SITC, Pharmaceutical industry, Vaccine, Research

SAN DIEGO and BASEL, Switzerland, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a biotechnology company developing next-generation precision immunotherapies to treat cancer and autoimmune disease, today announced the appointment of Jon Wigginton, M.D., as its President of Research and Development.

Key Points: 
  • SAN DIEGO and BASEL, Switzerland, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a biotechnology company developing next-generation precision immunotherapies to treat cancer and autoimmune disease, today announced the appointment of Jon Wigginton, M.D., as its President of Research and Development.
  • With a lifelong dedication to improving the lives of patients with cancer, Dr. Wigginton is an internationally recognized expert in immunotherapy drug development.
  • On behalf of the entire company and Board of Directors, I would like to welcome Jon to the team.
  • Prior, he was Chief Medical Officer at MacroGenics, where he led the companys evolution of a fully-integrated clinical-stage cancer immunotherapy organization.

Icario Names Healthcare Veteran Troy Jelinek Chief Commercial Officer

Retrieved on: 
Tuesday, April 12, 2022
Marketing, University, Health, GLOBE, Portland State University, Growth, Technology, Solution, Optum, Data science, Industry, UnitedHealth Group, Time, Wigginton, Management

MINNEAPOLIS, April 12, 2022 (GLOBE NEWSWIRE) -- Icario , the healthcare industrys largest health action company, today announced it has named Troy Jelinek chief commercial officer, a new senior executive position reporting to chief executive officer Steve Wigginton.

Key Points: 
  • MINNEAPOLIS, April 12, 2022 (GLOBE NEWSWIRE) -- Icario , the healthcare industrys largest health action company, today announced it has named Troy Jelinek chief commercial officer, a new senior executive position reporting to chief executive officer Steve Wigginton.
  • Jelinek was most recently on the executive leadership team and chief client officer at RubiconMD.
  • Troy brings a unique combination of experiences to the Icario team, having worked extensively with solutions that solve the challenges of healthcare payers and providers, said Wigginton.
  • Jelinek joins Icario from RubiconMD, which Oak Street Health recently acquired, where he served as executive vice president and chief client officer.

Checkmate Pharmaceuticals Welcomes Industry Leader Jon Wigginton, M.D. to its Board of Directors

Retrieved on: 
Monday, January 31, 2022
Immune system, University, Twitter, Securities Act of 1933, Board of directors, TLR9, COVID-19, CpG, File, B.S, GLOBE, Biology, Senior advisor, U.S. Securities and Exchange Commission, Review, Immunotherapy, Financial condition report, Society, Interim, Merck & Co., Analysis, Drug development, Security (finance), Society for Immunotherapy of Cancer, Leadership, Government, NASDAQ, National, Discovery, Result, Wigginton, Private Securities Litigation Reform Act, Bristol Myers Squibb, Clinical Oncology, BMS, Group medical practice in the United States, Forward-looking statement, Patient, Center, National Cancer Institute, SITC, Social media, Board, Lymphatic system, Annual report, SAB, Macrogen, LinkedIn, Director, Fine chemical, Pharmaceutical industry, Checkmate

to its Board of Directors (Board).

Key Points: 
  • to its Board of Directors (Board).
  • With his diverse background, he has driven numerous clinical stage immuno-oncology development portfolios, said Alan Fuhrman, Interim CEO and President of Checkmate.
  • Prior, he was Chief Medical Officer at MacroGenics, where he led the companys evolution of a fully-integrated clinical-stage cancer immunotherapy organization.
  • The information that Checkmate Pharmaceuticals posts on these channels and websites could be deemed to be material information.

THE NATIONAL CIVIL RIGHTS MUSEUM SELECTS RUSSELL WIGGINTON AS NEW PRESIDENT

Retrieved on: 
Thursday, July 1, 2021
United States, Activism, Social movements, Assassination of Martin Luther King Jr., Memorials to Martin Luther King Jr., National Civil Rights Museum, Civil rights movement, Martin Luther King Jr., Memphis, Tennessee, Wigginton

Memphis, TN, July 01, 2021 (GLOBE NEWSWIRE) -- After a five-month national search, the National Civil Rights Museum has named Dr. Russell Wigginton as the museums next president.

Key Points: 
  • Memphis, TN, July 01, 2021 (GLOBE NEWSWIRE) -- After a five-month national search, the National Civil Rights Museum has named Dr. Russell Wigginton as the museums next president.
  • I am honored to be chosen to serve as the President of the National Civil Rights Museum, said Wigginton.
  • Wigginton succeeds Terri Lee Freeman as museum president and will resign his museum board post to assume his new leadership role.
  • The NATIONAL CIVIL RIGHTS MUSEUM, located at the historic Lorraine Motel where civil rights leader Dr. Martin Luther King, Jr. was assassinated, gives a comprehensive overview of the American Civil Rights Movement from slavery to the present.

KaliVir Immunotherapeutics Appoints Drs. Terry Hermiston and Jon Wigginton to Board of Directors

Retrieved on: 
Thursday, June 17, 2021
Wigginton, Oncolytic virus, Sutro Biopharma

PITTSBURGH, June 17, 2021 /PRNewswire/ --KaliVir Immunotherapeutics, Inc., a privately held biotechnology company focused on the discovery and development of next generation oncolytic vaccinia virus immunotherapies, today announced the appointment of Terry Hermiston, Ph.D., and Jon Wigginton, M.D., to the company's board of directors.

Key Points: 
  • PITTSBURGH, June 17, 2021 /PRNewswire/ --KaliVir Immunotherapeutics, Inc., a privately held biotechnology company focused on the discovery and development of next generation oncolytic vaccinia virus immunotherapies, today announced the appointment of Terry Hermiston, Ph.D., and Jon Wigginton, M.D., to the company's board of directors.
  • I believe this program has an exciting future, and I'm pleased to be part of the team," stated Dr. Wigginton.
  • Terry Hermiston, Ph.D., brings over 25 years of biotechnology and pharmaceutical experience to KaliVir.
  • Dr. Wigginton also advises biotechnology companies and serves on the board of directors of Sutro Biopharma.

Icario Names Craig Wigginton Chief Technology Officer

Retrieved on: 
Tuesday, May 25, 2021
Articles, Wigginton, Digital transformation

MINNEAPOLIS, May 25, 2021 (GLOBE NEWSWIRE) -- Icario , the healthcare industrys largest health action company, today named digital transformation leader Craig Wigginton as Chief Technology Officer.

Key Points: 
  • MINNEAPOLIS, May 25, 2021 (GLOBE NEWSWIRE) -- Icario , the healthcare industrys largest health action company, today named digital transformation leader Craig Wigginton as Chief Technology Officer.
  • Wigginton joins Icario from Altruista Health, where he served as CTO, working closely with health plans across the United States and leading a global team of more than 400 product, technology, and implementation professionals.
  • "Craig is an expert in harnessing technology to improve healthcare and he is also a world-class leader and teammate," said Steve Wigginton, CEO at Icario.
  • His deep knowledge of both technology and healthcare further strengthens our foundation and will allow us to accelerate innovation for our clients.